Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

N. Gupta, H. Yang, MJ. Hanley, S. Zhang, R. Liu, S. Kumar, PG. Richardson, T. Skacel, K. Venkatakrishnan,

. 2017 ; 12 (5) : 643-654.

Jazyk angličtina Země Francie

Typ dokumentu klinické zkoušky, fáze I, klinické zkoušky, fáze II, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033780
E-zdroje Online Plný text

NLK ProQuest Central od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 2006-01-01 do 2017-12-31

Odkazy

PubMed 28803351
DOI 10.1007/s11523-017-0524-3
Knihovny.cz E-zdroje

BACKGROUND: The oral proteasome inhibitor ixazomib has been approved by regulatory authorities around the world, including in the United States and the European Union, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy, based on the pivotal phase III TOURMALINE-MM1 study. OBJECTIVE: The objective of this study was to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM in support of the approved dose and schedule. METHODS: We report early-phase study data and exposure-response analyses of TOURMALINE-MM1 data that support the selection of the recommended ixazomib dose and schedule. RESULTS: Single-agent ixazomib studies showed a favorable efficacy/safety profile with weekly versus twice-weekly dosing; a phase I/II study of ixazomib in combination with lenalidomide and dexamethasone (IRd) identified a weekly ixazomib dose that offered an acceptable efficacy/safety profile. In IRd exposure-response analyses from TOURMALINE-MM1, ixazomib systemic exposure was not a significant predictor of progression-free survival or probability of response. Significant associations were observed between ixazomib exposure and the probability of grade ≥3 anemia and thrombocytopenia, and grade ≥2 diarrhea, fatigue, nausea, peripheral neuropathy, and rash. Additionally, higher ixazomib exposure was associated with lower lenalidomide relative dose intensity. CONCLUSIONS: These analyses support a favorable benefit-risk profile for weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28-day cycles, which was selected for the phase III TOURMALINE registration program. TRIAL REGISTRATION NUMBERS: ClinicalTrials.gov NCT00932698, NCT00963820, NCT01217957, NCT01564537.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033780
003      
CZ-PrNML
005      
20181015102410.0
007      
ta
008      
181008s2017 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11523-017-0524-3 $2 doi
035    __
$a (PubMed)28803351
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Gupta, Neeraj $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Neeraj.Gupta@takeda.com.
245    10
$a Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses / $c N. Gupta, H. Yang, MJ. Hanley, S. Zhang, R. Liu, S. Kumar, PG. Richardson, T. Skacel, K. Venkatakrishnan,
520    9_
$a BACKGROUND: The oral proteasome inhibitor ixazomib has been approved by regulatory authorities around the world, including in the United States and the European Union, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy, based on the pivotal phase III TOURMALINE-MM1 study. OBJECTIVE: The objective of this study was to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM in support of the approved dose and schedule. METHODS: We report early-phase study data and exposure-response analyses of TOURMALINE-MM1 data that support the selection of the recommended ixazomib dose and schedule. RESULTS: Single-agent ixazomib studies showed a favorable efficacy/safety profile with weekly versus twice-weekly dosing; a phase I/II study of ixazomib in combination with lenalidomide and dexamethasone (IRd) identified a weekly ixazomib dose that offered an acceptable efficacy/safety profile. In IRd exposure-response analyses from TOURMALINE-MM1, ixazomib systemic exposure was not a significant predictor of progression-free survival or probability of response. Significant associations were observed between ixazomib exposure and the probability of grade ≥3 anemia and thrombocytopenia, and grade ≥2 diarrhea, fatigue, nausea, peripheral neuropathy, and rash. Additionally, higher ixazomib exposure was associated with lower lenalidomide relative dose intensity. CONCLUSIONS: These analyses support a favorable benefit-risk profile for weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28-day cycles, which was selected for the phase III TOURMALINE registration program. TRIAL REGISTRATION NUMBERS: ClinicalTrials.gov NCT00932698, NCT00963820, NCT01217957, NCT01564537.
650    _2
$a protinádorové látky $x aplikace a dávkování $7 D000970
650    _2
$a sloučeniny boru $x aplikace a dávkování $7 D001896
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glycin $x aplikace a dávkování $x analogy a deriváty $7 D005998
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a inhibitory proteasomu $x aplikace a dávkování $7 D061988
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yang, Huyuan $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
700    1_
$a Hanley, Michael J $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
700    1_
$a Zhang, Steven $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
700    1_
$a Liu, Rachael $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
700    1_
$a Kumar, Shaji $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Richardson, Paul G $u Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Skacel, Tomas $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. Department of Hematology, Charles University General Hospital, Prague, Czech Republic.
700    1_
$a Venkatakrishnan, Karthik $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
773    0_
$w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 12, č. 5 (2017), s. 643-654
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28803351 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181015102906 $b ABA008
999    __
$a ok $b bmc $g 1340290 $s 1030774
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 5 $d 643-654 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace